To gain a clearer insight into the clinical relevance of KLHDC8A, we performed in silico analysis of TCGA data, revealing that KLHDC8A was preferentially expressed in glioblastoma tissues compared with normal brain tissues, and its expression, along with that of SMO, GLI1, and ARL13B, correlated with mesenchymal and classical subtypes, WT IDH tumors, high-grade glioma, and older patients (Figure 9, A–D). The gene discussed is SMO; the disease is central nervous system cancer.